09/10/2026
We are pleased to see these four FDA senior leadership appointments at such a critical time for people living with rare diseases. Stability, certainty and strong leadership are essential to advancing regulatory science.
Rare diseases are a significant public health issue affecting more than 30 million Americans, most of which have no approved therapy. NORD looks forward to working with our new leaders to advance innovation and ensure the needs of people living with rare diseases remain at the forefront of the FDA’s work.